Natco Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Natco Pharma Ltd · Outcome · 13 Nov 2026, 7:43 pm
Natco Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 9,673 (-29.0% YoY | +31.6% QoQ) ■ EBITDA: 2,579 (-55.5% YoY | +38.3% QoQ) ■ EBITDA Margin (%): 26.7 (-1583 bps YoY | +129 bps QoQ) ■ PAT: 2,026 (-60.9% YoY | -1.9% QoQ) ■ EPS (INR): 11.3 (-60.9% YoY | -1.9% QoQ) Natco Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Pharmaceuticals ■ Revenue: 9,063 (-30.8% YoY | +30.5% QoQ) ■ EBIT: 2,607 (-58.8% YoY | +27.9% QoQ) ■ EBIT Margin (%): 28.8 (-1957 bps YoY | -60 bps QoQ) Agro chemicals ■ Revenue: 610 (+16.2% YoY | +49.5% QoQ) ■ EBIT: 1.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 0.2 (Loss to Profit YoY | Loss to Profit QoQ)
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet · 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 · 14 Nov 2026
- Q2 FY27 Earnings Presentation · 13 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 · 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 · 13 Nov 2026
- Intimation of schedule of Concall · 13 Nov 2026
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni · 04 Nov 2026
